The plasma fractionation market involves the separation of plasma components to produce life-saving therapies used in treating immune deficiencies, bleeding disorders, and other medical conditions. Key plasma-derived products include immunoglobulins, albumin, coagulation factors, and protease inhibitors. These products play a crucial role in immunology, hematology, neurology, and critical care medicine. Market growth is driven by the increasing prevalence of chronic and rare diseases, rising demand for plasma-derived therapies, and advancements in fractionation technology that enhance yield and purity. Additionally, the growing use of immunoglobulins in autoimmune and inflammatory diseases is a major factor fueling demand.
The global plasma fractionation market size was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a CAGR of 8.75% during the forecast period. The market growth is driven by the increasing prevalence of chronic diseases, advancements in plasma-derived therapies, and the rising demand for immunoglobulins and coagulation factors across the globe. North America dominated the plasma fractionation market with a market share of 56.18% in 2024, attributed to its well-established healthcare infrastructure, strong donor base, advanced production facilities, and the presence of major players such as CSL Behring, Grifols, Takeda Pharmaceutical, and Kedrion Biopharma.
The Fortune Business Insights report provides a detailed overview of the plasma fractionation industry, covering market size, share, segmentation, regional insights, competitive landscape, product pipeline, and post-COVID recovery analysis. The study offers a holistic view of key trends shaping the global plasma fractionation landscape.
These players drive the market through strategic initiatives such as expanding plasma-collection networks, investing in R&D, launching new therapeutics, and leveraging regulatory approvals.